A Randomized, Double-blind, Parallel Pharmacokinetic Study Comparing the Trastuzumab Biosimilar Candidate, AryoTrust ®, and Reference Trastuzumab in Healthy Subjects.

CONCLUSION: AryoTrust® was well tolerated, had a similar safety profile to reference trastuzumab, and its pharmacokinetic bioequivalence was confirmed. Trial Registration The trial is registered at Indian Trials Registry (CTRI/2019/03/018218). PMID: 33016783 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33016783?dopt=Abstract

Source: Expert Opinion on Investigational Drugs - October 7, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research